Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.

Elizabeth Grace Carideo Cunniff,Julie Zhang,Jouhara Chouitar,Jerome Mettetal,Kazuhide Nakamura,Takeo Arita,Akito Nakamura,Masanori Okaniwa,Tomoyasu Ishikawa,Sei Yoshida,Robyn Fabrey,Patrick Vincent,Kurt Eng,Khristofer Garcia,Deanna Borrelli,Teena Vagrhese,Steve Stroud,Saurabh Menon,Mike Kuranda,Katherine M. Galvin

Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.

2013

e13529 Background: RAS mutant melanoma and colorectal cancer represent areas of significant unmet medical need. MLN2480 is an investigational class II RAF kinase inhibitor and TAK-733 is an investi...

Keywords:

Melanoma
Raf Kinase Inhibitor
Cancer research
Mutant
Medicine
Kinase
combined treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations